ClinicalTrials.gg
Active, not recruitingNCT05899608Updated Oct 8, 2026

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

A Phase 3 interventional study of Ivonescimab Injection and Pembrolizumab Injection in Non-Small Cell Lung Cancer, sponsored by Summit Therapeutics. Active, not recruiting at 260 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Summit Therapeutics · Phase 3, Interventional, and Treatment

Updated Oct 8, 2026Now Active, not recruiting1 site added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,600
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung — 23 open to participants now, 30 under way, 7 of them phase 3. ivonescimab · Carcinoma, Non-Small-Cell Lung.

Planned enrollment
Largest of 31
1,600 · median 70
Started
2023
with 3 others
Phase 3
7 of 31
2 open now
Primary completion
2028-12
later than 27 of 29 live
Registered
7th of 31
by date
Lead sponsor
3 of 31
Summit Therapeutics

Among the 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung, this one has the largest planned enrollment, is one of 4 that started in 2023, is one of 7 in phase 3, reaches primary completion later than 27 of the 29 other live ones, and was the 7th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,837 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

23 of the 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:

18 more — sign in →

By country, each count listing its studies:

All 23 open studies →

About ivonescimab

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 1,326 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing ivonescimab in Carcinoma, Non-Small-Cell Lung, or all of them as a file.
02

Study summary

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.

Read the detailed description

This study consists of two distinct NSCLC histology cohorts: squamous (N=600) and non-squamous (N=1000), approximately 1600 patients in total. Within each cohort, subjects are randomized in a 1:1 ratio into one of two treatment groups, receiving either ivonescimab or pembrolizumab combined with platinum-doublet chemotherapy. The two histology cohorts will be analyzed independently

03

Conditions studied

  • Non-Small Cell Lung Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 18 years old at the time of enrollment
  • (ECOG) performance status score of 0 or 1
  • Expected ≥ 3 months
  • (Stage IV) NSCLC
  • or cytologically confirmed squamous or non-squamous NSCLC
  • Recorded measurement of the Tumor Proportion Score (TPS) or Tumor Cells (TC) for expression, irrespective of the PD-L1 expression, prior to randomization
  • At least one measurable noncerebral lesion according to 1.1
  • No prior systemic treatment for metastatic NSCLC

Exclusion criteria

Exclusion Criteria:

  • Histologic or cytopathologic evidence of the presence of small cell lung carcinoma
  • Known actionable genomic alterations (EGFR, ALK, ROS1, and BRAF V600E) or genes for which approved therapies are available.

    • For non-squamous histology patients, actionable driver mutation testing results are required before randomization.
  • Has received any prior therapy for NSCLC in the setting
  • Tumor invasion, encasement of organs (e.g. pericardium, heart, trachea, esophagus, central bronchi), or major blood vessels (e.g aorta, central veins), if poses a significant increased risk of bleeding.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,600 participants (estimated)

Study arms

  • Experimental
    Arm A - Ivonescimab and chemotherapy

    Subject will receive ivonescimab and chemotherapy

    Biological: Ivonescimab Injection

  • Active comparator
    Arm B - Pembrolizumab and chemotherapy

    Subject will receive pembrolizumab and chemotherapy

    Biological: Pembrolizumab Injection

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    Overall Survival (OS) in the ITT population

    Time frame: approximately 4 years

  2. Progression Free Survival (PFS)

    Progression Free Survival (PFS) assessed by investigator based on RECIST V1.1

    Time frame: approximately 3 years

Secondary outcomes

  1. Adverse Event (AE)

    incidence and severity of adverse events (AEs) and clinically significant abnormal laboratory test results

    Time frame: From the subject signs the ICF to 30 days (AE) and 90 days (SAE related to ivonescimab/pembrolizumab ) after the last dose of study treatment or initiation of other anticancer therapy, whichever occurs first, up to 2 years.

07

Study locations

260 sites

Showing the first 100 of 260 sites across 17 countries. Choose a country and city above to see the rest.

08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Dec 2028, 62 months after the start.

Of 315 industry-sponsored phase 3 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 57. This study's planned 62 months is above that.

Counting every sponsor, half of 424 studies reached it within 45 months; a quarter within 30 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2023
First posted
Jun 12, 2023
StartActual
Oct 26, 2023
Primary completionEst.
Dec 31, 2028
CompletionEst.
Dec 31, 2029
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 8, 2026
Sites
1 site added, 1 site removed
Show site
  • The Cancer institute Hospital of JFCR · Tokyo, Japan
Show 1 removed
  • The Cancer institute Hospital · Tokyo, Japan
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Recruiting→Active, not recruiting
    1 site added, 1 site removed
    Show site
    • The Cancer institute Hospital of JFCR · Tokyo, Japan
    Show 1 removed
    • The Cancer institute Hospital · Tokyo, Japan
    + 2 other changes: verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05899608
Lead sponsor
Summit Therapeutics
Responsible party
Sponsor
First posted
Jun 12, 2023
Start date
Oct 26, 2023
Primary completion
Dec 31, 2028 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 8, 2026

Study contacts

Indu Lal
study director · Summit Therapeutics, Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivonescimab

Start the discussion